undamentalytics Newsletter

Denner Alexander J: insider trades

Director, 10% owner at 3 companies we cover. 11 open-market purchases and 2 sales not made under a pre-set plan, reported from October 26, 2015 to March 17, 2026.

Would copying Denner Alexander J’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 11 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on October 27, 2015 into $17,328 by November 2, 2026, +5.1% a year. The copy held shares only 55% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $22,446, +7.6% a year (the S&P 500 held throughout made $43,799, +14.4% a year). Beta against the index was 0.49. Twelve months after each report, the average purchase was −8.4% against the S&P 500 (median −10.1%), and 18% beat it. Measured from the trade date, the insider’s own timing, the average was −6.6%. After their sales, the shares moved +8.1% against the index over 12 months on average (a negative figure means selling was the right call); 0% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 201520172019202120232025 $43.8k$22.4k$17.3k
Copying Denner Alexander JS&P 500, same days investedS&P 500, held throughout $10,000 copying Denner Alexander J’s open-market purchases from October 27, 2015, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+5.1%
S&P 500, same days invested
+7.6% (held throughout +14.4%)
Time in shares
55%
Sharpe ratio (S&P 500)
0.23 (0.72)
Biggest drop (S&P 500)
−44% (−34%)
Market sensitivity (beta)
0.49
Purchases copied
11

Trade by trade

Denner Alexander J: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 11 −4.2% −0.6% 46% 6 −0.39 0.71 No reliable evidence
Purchases, 6 months after the report 11 −0.5% 0.0% 55% 6 0.08 0.94 No reliable evidence
Purchases, 12 months after the report 11 −8.4% −10.1% 18% 6 −2.40 0.062 No reliable evidence
Purchases, 12 months after the trade 11 −6.6% −5.5% 27% 6 −1.98 0.10 No reliable evidence
Sales, 3 months after the report 1 +18.0% +18.0% 0% 1 — — Not enough years
Sales, 12 months after the report 1 +8.1% +8.1% 0% 1 — — Not enough years
Sales, 12 months after the trade 1 +6.7% +6.7% 0% 1 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Biogen BIIB —60October 26, 2015May 2, 2019
Innoviva, Inc. INVA —31May 15, 2023March 6, 2025
Ironwood Pharmaceuticals Inc IRWD —21March 2, 2021March 17, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
March 17, 2026March 17, 2026 IRWD Sale $20,530,448 not yetnot yetnot yet
March 6, 2025March 4, 2025 INVA Sale $28,398,899 +18.0%+8.1%+6.7%
June 7, 2023June 5, 2023 INVA Purchase $195,680 −12.2%−10.5%−5.5%
May 30, 2023May 25, 2023 INVA Purchase $2,609,300 −12.4%−11.0%−11.3%
May 15, 2023May 11, 2023 INVA Purchase $3,578,600 −5.1%−10.1%+2.0%
March 5, 2021March 3, 2021 IRWD Purchase $7,758,750 +6.6%+1.4%−6.9%
March 2, 2021February 26, 2021 IRWD Purchase $12,737,960 +6.6%−6.9%+3.0%
May 2, 2019April 30, 2019 BIIB Purchase $27,211,824 +4.8%+29.9%+31.2%
February 1, 2019January 30, 2019 BIIB Purchase $20,572,366 −37.5%−38.5%−40.1%
April 27, 2018April 25, 2018 BIIB Purchase $12,955,680 +14.8%−28.6%−27.9%
November 30, 2017November 28, 2017 BIIB Purchase $9,520,800 −14.2%−3.5%−1.6%
May 1, 2017April 27, 2017 BIIB Purchase $20,569,476 +3.2%−11.3%−13.8%
October 26, 2015October 22, 2015 BIIB Purchase $86,015,000 −0.6%−3.7%−1.5%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Denner Alexander J traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.